Empagliflozin in HF with Preserved Ejection Fraction
Sodium–glucose cotransporter 2 inhibitors have been shown to improve outcomes in patients with heart failure and a reduced ejection fraction, but whether they improve outcomes in patients with a preserved ejection fraction is uncertain. New research findings are summarized in a short video.
Copyright © 2021 Massachusetts Medical Society.
